These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 2549845)

  • 1. The pedunculopontine nucleus in Parkinson's disease.
    Zweig RM; Jankel WR; Hedreen JC; Mayeux R; Price DL
    Ann Neurol; 1989 Jul; 26(1):41-6. PubMed ID: 2549845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of pedunculopontine neurons in progressive supranuclear palsy.
    Zweig RM; Whitehouse PJ; Casanova MF; Walker LC; Jankel WR; Price DL
    Ann Neurol; 1987 Jul; 22(1):18-25. PubMed ID: 3631916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra.
    Rinne JO; Rummukainen J; Paljärvi L; Rinne UK
    Ann Neurol; 1989 Jul; 26(1):47-50. PubMed ID: 2549846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of cholinergic neurons in the pedunculopontine nucleus in Parkinson's disease is related to disability of the patients.
    Rinne JO; Ma SY; Lee MS; Collan Y; Röyttä M
    Parkinsonism Relat Disord; 2008 Nov; 14(7):553-7. PubMed ID: 18329941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurofilament mRNA is reduced in Parkinson's disease substantia nigra pars compacta neurons.
    Hill WD; Arai M; Cohen JA; Trojanowski JQ
    J Comp Neurol; 1993 Mar; 329(3):328-36. PubMed ID: 8459049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parkinson's disease: neuron loss in the nucleus basalis without concomitant Alzheimer's disease.
    Nakano I; Hirano A
    Ann Neurol; 1984 May; 15(5):415-8. PubMed ID: 6732189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease.
    Halliday GM; Li YW; Blumbergs PC; Joh TH; Cotton RG; Howe PR; Blessing WW; Geffen LB
    Ann Neurol; 1990 Apr; 27(4):373-85. PubMed ID: 1972319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurofibrillary tangles in cholinergic pedunculopontine neurons in Alzheimer's disease.
    Mufson EJ; Mash DC; Hersh LB
    Ann Neurol; 1988 Nov; 24(5):623-9. PubMed ID: 3202615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson's, Alzheimer's with parkinsonism, and Alzheimer's disease.
    Joyce JN; Smutzer G; Whitty CJ; Myers A; Bannon MJ
    Mov Disord; 1997 Nov; 12(6):885-97. PubMed ID: 9399211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuronal loss in the substantia nigra in patients with Alzheimer's disease and Parkinson's disease in relation to extrapyramidal symptoms and dementia.
    Rinne JO; Rummukainen J; Paljärvi L; Säkö E; Mölsä P; Rinne UK
    Prog Clin Biol Res; 1989; 317():325-32. PubMed ID: 2602422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease.
    Sasaki M; Shibata E; Tohyama K; Takahashi J; Otsuka K; Tsuchiya K; Takahashi S; Ehara S; Terayama Y; Sakai A
    Neuroreport; 2006 Jul; 17(11):1215-8. PubMed ID: 16837857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The neuropathology of aminergic nuclei in Alzheimer's disease.
    Zweig RM; Ross CA; Hedreen JC; Steele C; Cardillo JE; Whitehouse PJ; Folstein MF; Price DL
    Ann Neurol; 1988 Aug; 24(2):233-42. PubMed ID: 3178178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progressive supranuclear palsy affects both the substantia nigra pars compacta and reticulata.
    Hardman CD; Halliday GM; McRitchie DA; Cartwright HR; Morris JG
    Exp Neurol; 1997 Mar; 144(1):183-92. PubMed ID: 9126169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [MRI in Parkinson's disease and vascular parkinsonism--study on the lesion of substantia nigra].
    Aotsuka A; Shinotoh H; Hirayama K; Ikehira H; Fukuda H
    Rinsho Shinkeigaku; 1991 Jun; 31(6):619-24. PubMed ID: 1934776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with parkinsonism.
    Murray AM; Weihmueller FB; Marshall JF; Hurtig HI; Gottleib GL; Joyce JN
    Ann Neurol; 1995 Mar; 37(3):300-12. PubMed ID: 7695230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution--a pilot study.
    Jellinger KA
    Acta Neuropathol; 2003 Sep; 106(3):191-201. PubMed ID: 12845452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic reorganisation in the basal forebrain under degenerative conditions and its defects in Alzheimer's disease. III. The basal forebrain compared with other subcortical areas.
    Arendt T; Brückner MK; Bigl V; Marcova L
    J Comp Neurol; 1995 Jan; 351(2):223-46. PubMed ID: 7699112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and neurochemical consequences of neuronal loss in the nucleus basalis of Meynert in Parkinson's disease and Alzheimer's disease.
    Whitehouse PJ
    Adv Neurol; 1987; 45():393-7. PubMed ID: 2881448
    [No Abstract]   [Full Text] [Related]  

  • 20. Pathological correlates of extrapyramidal signs in Alzheimer's disease.
    Liu Y; Stern Y; Chun MR; Jacobs DM; Yau P; Goldman JE
    Ann Neurol; 1997 Mar; 41(3):368-74. PubMed ID: 9066358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.